Publikationen 2024

87. AIDS-defining events among people living with HIV who have been under continuous antiretroviral therapy for more than one year, a German cohort study 1999-2018. Pantke A, Kollan C, Gunsenheimer-Bartmeyer B, Jensen BO, Stephan C, Degen O, Schürmann D, Kurth T, Bremer V, Koppe U; HIV-1 Seroconverter Cohort and the ClinSurv HIV Cohort. Infection. 2024 Apr;52(2):637-648. Epub 2024 Feb 21.

86. The trajectory of anti-recEm18 antibody levels determines follow-up after curative resection of hepatic alveolar echinococcosis. Gloor S, Jiang W, Maurer MH, Gottstein B, Oberli A, Hagemann JB, Hotz JF, Candinas D, Lachenmayer A, Grüner B, Beldi G. HPB (Oxford). 2024 Feb;26(2):224-233. Epub 2023 Oct 10.

85. Characterising HIV-Indicator conditions among two nationwide long-term cohorts of people living with HIV in Germany (1999-2023). Krings A, Kollan C, Schmidt D, Gunsenheimer-Bartmeyer B, Valbert F, Neumann A, Wasem J, Behrens GMN, Bickel M, Boesecke C, Esser S, Dröge P, Ruhnke T, Koppe U; HIV-1 Seroconverter, ClinSurv-HIV study groups. Infection. 2024 Oct 30. doi: 10.1007/s15010-024-02419-2. Online ahead of print. PMID: 39476279

84. Pre-existing sleep problems as a predictor of post-acute sequelae of COVID-19. Schilling C, Nieters A, Schredl M, Peter RS, Rothenbacher D, Brockmann SO, Göpel S, Kindle G, Merle U, Steinacker JM, Kern W; Epidemiology of Long COVID (EPILOC) Phase I study group. J Sleep Res. 2024 Apr;33(2):e13949. Epub 2023 May 25.

83. Effectiveness of the BNT162b2 XBB.1.5-adapted vaccine against COVID-19 hospitalization related to the JN.1 variant in Europe: a test-negative case-control study using the id.DRIVE platform. Nguyen JL, Mitratza M, Volkman HR, de Munter L, Tran TMP, Marques C, Mustapha M, Valluri S, Yang J, Antón A, Casas I, Conde-Sousa E, Drikite L, Grüner B, Icardi G, Ten Kate GL, Martin C, Mira-Iglesias A, Orrico-Sánchez A, Otero-Romero S, Rohde G, Jodar L, McLaughlin JM, Bollaerts K. EClinicalMedicine. 2024 Dec 9;79:102995. eCollection 2025 Jan.

82. Comparison of fludarabine/melphalan (FM140) with fludarabine/melphalan/BCNU (FBM110) in patients with relapsed/refractory AML undergoing allogeneic hematopoietic cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working Party. Duque-Afonso J, Finke J, Ngoya M, Galimard JE, Schetelig J, Eder M, Rösler W, Bug G, Neubauer A, Edinger M, Wulf GG, Jindra P, Einsele H, Stelljes M, Selleslag D, Wagner-Drouet EM, Bunjes D, Spyridonidis A, Brissot E, Nagler A, Ciceri F, Mohty M. Bone Marrow Transplant. 2024 Dec 19. doi: 10.1038/s41409-024-02499-6. Online ahead of print. PMID: 39702670

81. Standardized Response Assessment in Patients with Advanced Cholangiocarcinoma Treated with Personalized Therapy. Ursprung S, Thaiss W, Beha J, Möller Y, Malek NP, Beer M, Gaidzik VI, Seufferlein T, Beer AJ, Nikolaou K, Reinert CP. J Pers Med. 2024 Dec 6;14(12):1143.

80. Impaired SARS-CoV-2-Specific CD8+ T Cells After Infection or Vaccination but Robust Hybrid T Cell Immunity in Patients with Multiple Myeloma. Shoumariyeh K, Csernalabics B, Salimi Alizei E, Reinscheid M, Giese S, Ciminski K, Kochs G, Schwemmle M, Lang-Meli J, Maas M, Roehlen N, Karl V, Graeser A, Sogukpinar O, von Metzler I, Grathwohl D, Rasche L, Hebart H, Kull M, Emmerich F, Waller CF, Duyster J, Engelhardt M, Hartmann TN, Bengsch B, Boettler T, Neumann-Haefelin C, Hofmann M, Thimme R, Luxenburger H. Vaccines (Basel). 2024 Nov 1;12(11):1249.

79. Risk-stratification in frontline CLL therapy: standard of care. Tausch E, Schneider C, Stilgenbauer S. Hematology Am Soc Hematol Educ Program. 2024 Nov 25;2024(1):457-466.

78. Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL. Chatzikonstantinou T, Scarfò L, Minga E, Karakatsoulis G, Chamou D, Kotaskova J, Iacoboni G, Demosthenous C, Albi E, Alcoceba M, Al-Shemari S, Aurran-Schleinitz T, Bacchiarri F, Chatzileontiadou S, Collado R, Davis Z, de Deus Santos MD, Dimou M, Dmitrieva E, Donaldson D, Dos Santos G, Dreta B, Efstathopoulou M, El-Ashwah S, Enrico A, Frygier A, Galimberti S, Galitzia A, Gimeno E, Guarente V, Guieze R, Harrop S, Hatzimichael E, Herishanu Y, Hernández-Rivas JÁ, Jaksic O, Kalicińska E, Laribi K, Karakus V, Kater AP, Kho B, Kislova M, Konstantinou Ε, Koren-Michowitz M, Kotsianidis I, Kubova Z, Labrador J, Lad D, Laurenti L, Longval T, Lopez-Garcia A, Marquet J, Maslejova S, Mayor-Bastida C, Mihaljevic B, Milosevic I, Miras F, Moia R, Morawska M, Nath UK, Navarro-Bailón A, Olivieri J, Panovska-Stavridis I, Papaioannou M, Pierie C, Puiggros A, Reda G, Rigolin GM, Ruchlemer R, Schipani M, Schiwitza A, Shen Y, Shokralla T, Simkovic M, Smirnova S, Soliman DSA, Stilgenbauer S, Tadmor T, Tomic K, Tse E, Vassilakopoulos T, Visentin A, Vitale C, Vrachiolias G, Vukovic V, Walewska R, Xu Z, Yagci M, Yañez L, Yassin M, Zuchnicka J, Oscier D, Gozzetti A, Panagiotidis P, Bosch F, Sportoletti P, Espinet B, Pangalis GA, Popov VM, Mulligan S, Angelopoulou M, Demirkan F, Papajík T, Biderman B, Murru R, Coscia M, Tam C, Cuneo A, Gaidano G, Claus R, Stavroyianni N, Trentin L, Antic D, Smolej L, Kalashnikova OB, Catherwood M, Spacek M, Pospisilova S, Doubek M, Nikitin E, Chatzidimitriou A, Ghia P, Stamatopoulos K. Hemasphere. 2024 Sep 17;8(9):e70004. eCollection 2024 Sep.

77. Long-Term Follow-Up of the Prospective Randomized AATT Study (Autologous or Allogeneic Transplantation in Patients With Peripheral T-Cell Lymphoma). Tournilhac O, Altmann B, Friedrichs B, Bouabdallah K, Leclerc M, Cartron G, Turlure P, Reimer P, Wagner-Drouet E, Sanhes L, Houot R, Roussel M, Kroschinsky F, Dreger P, Viardot A, de Leval L, Rosenwald A, Gaulard P, Wulf G, Villate A, Latiere C, Elmaagacli A, Glass B, Poeschel V, Damaj G, Sibon D, Durot E, Bilger K, Banos A, Haenel M, Dreyling M, Keller U, Tiab M, Drenou B, Cornillon J, Nguyen S, Robin M, Nickelsen M, Trümper L, Lenz G, Ziepert M, Schmitz N; French Lymphoma Study Association (LYSA); Société Francophone de greffe de moelle et Thérapie Cellulaire (SFGM-TC); German Lymphoma Alliance (GLA); French Lymphoma Study Association (LYSA), Société Francophone de greffe de moelle et Thérapie Cellulaire (SFGM-TC), German Lymphoma Alliance (GLA). J Clin Oncol. 2024 Nov 10;42(32):3788-3794. Epub 2024 Sep 13.

76. Continued decitabine/all-trans retinoic acid treatment: extended complete remission in an elderly AML patient with multi-hit TP53 lesions and complex-monosomal karyotype. Thomas J, Rehman UU, Bresser H, Grishina O, Pfeifer D, Sollier E, Döhner K, Plass C, Becker H, Schmoor C, de Wit M, Lübbert M. Clin Epigenetics. 2024 Sep 11;16(1):126.

75. Human immunodeficiency virus-associated Lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Hübel K, Bower M, Aurer I, Bastos-Oreiro M, Besson C, Brunnberg U, Cattaneo C, Collins S, Cwynarski K, Pria AD, Hentrich M, Hoffmann C, Kersten MJ, Montoto S, Navarro JT, Oksenhendler E, Re A, Ribera JM, Schommers P, von Tresckow B, Buske C, Dreyling M, Davies A; EHA and ESMO Guidelines Committees. Hemasphere. 2024 Sep 3;8(9):e150. eCollection 2024 Sep.

74. A high proportion of germline variants in pediatric chronic myeloid leukemia. Krumbholz M, Dolnik A, Sträng E, Ghete T, Skambraks S, Hutter S, Simonis A, Stegelmann F, Suttorp M, Horn AHC, Sticht H, Haferlach T, Bullinger L, Metzler M. Mol Cancer. 2024 Sep 26;23(1):206.

73. Measurable Residual Disease Monitoring in AML With FLT3-ITD Treated With Intensive Chemotherapy Plus Midostaurin. Rücker FG, Bullinger L, Cocciardi S, Skambraks S, Luck TJ, Weber D, Krzykalla J, Pozek E, Schneider IJ, Corbacioglu A, Gaidzik VI,Meid A Dr, Aicher S, Stegelmann F, Schrade A,Theis F, Fiedler W, Salih HR, Wulf GG, Salwender HJ, Schroeder T, Götze KS, Kühn MWM, Lübbert M, Schlenk RF, Benner A, Thol FR, Heuser M, Ganser A, Döhner H, Döhner K. Blood Adv. 2024 Dec 10;8(23):6067-6080.

72. Outcomes of Haploidentical Transplants with PT-CY versus 10/10 MUD Transplants with ATG in Germany. Arslan A, Labuhn S, Sala E, Ringhoffer M, Schetelig J, Schroeder T, Bug G, Franke GN, Stelljes M, Dreger P, Zeiser R, Teschner D, Bethge WA, Eder M, Edinger M, Amann EM, Neuchel C, Schmid-Möglich A, Schmeller S, Beyersmann J, Schrezenmeier H, Mytilineos J, Kröger N, Fuerst D. Blood Adv. 2024 Dec 10;8(23):6104-6113.

71. How to optimize the CAR-T Cell therapy process? A group concept mapping analysis of preconditions for a frictionless process from a German multistakeholder perspective. Siefen AC, Kurte MS, Jakobs F, Teichert M, von Tresckow B, Reinhardt HC, Holtick U, Atta J, Jehn C, Sala E, Warnecke A, Hänel M, Scheid C, Kron F. Front Oncol. 2024 Sep 23;14:1466803. eCollection 2024.

70. Desmoplastic Small Round Cell Tumors: Clinical Presentation, Molecular Characterization, and Therapeutic Approach of Seven Patients. Gaidzik VI, Mayer-Steinacker R, Wittau M, Schultheiß M, V Baer A, Oehl-Huber K, Dahlum S, Fischer A, Gerstenmaier U, Seufferlein T, Buck A, Beer A, Thaiss W, Möller P, Döhner H, Siebert R, Marienfeld R, Barth TFE. Sarcoma. 2024 Oct 8;2024:5036102.

69. repDilPCR: a tool for automated analysis of qPCR assays by the dilution-replicate method. Yosifov DY, Reichenzeller M, Stilgenbauer S, Mertens D. BMC Bioinformatics. 2024 Oct 15;25(1):331.

68. Immunotherapeutic Potential of Mutated NPM1 for the Treatment of Acute Myeloid Leukemia. Greiner J, Mohamed E, Fletcher DM, Schuler PJ, Schrezenmeier H, Götz M, Guinn BA. Cancers (Basel). 2024 Oct 10;16(20):3443.

67. Evaluation and management of hepatic dysfunction, portal hypertension and portal/splanchnic vein thrombosis in patients with myelofibrosis undergoing allogeneic haematopoietic cell transplantation: A practice based survey on behalf of the Chronic Malignancies Working Party of the EBMT. Battipaglia G, Polverelli N, Tuffnell J, Chiusolo P, Robin M, Gambella M, Broers A, Sala E, Passweg J, Furst S, Friis LS, Dulery R, de Witte M, Srour M, Finazzi MC, Wehr C, Nagler A, Richardson D, Bethge W, Clark A, Drozd-Sokolowska J, Raj K, Czerw T, Hernández-Boluda JC, McLornan DP. Curr Res Transl Med. 2024 Oct 25;73(1):103476.

66. The NOTCH1 and miR-34a signaling network is affected by TP53 alterations in CLL. Ehrmann AS, Zadro A, Tausch E, Schneider C, Stilgenbauer S, Mertens D. Leuk Lymphoma. 2024 Dec;65(13):1941-1953. Epub 2024 Aug 19.

65. Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients. Halik A, Tilgner M, Silva P, Estrada N, Altwasser R, Jahn E, Heuser M, Hou HA, Pratcorona M, Hills RK, Metzeler KH, Fenwarth L, Dolnik A, Terre C, Kopp K, Blau O, Szyska M, Christen F, Krönke J, Vasseur L, Löwenberg B, Esteve J, Valk PJM, Duchmann M, Chou WC, Linch DC, Döhner H, Gale RE, Döhner K, Bullinger L, Yoshida K, Damm F. J Hematol Oncol. 2024 Aug 19;17(1):70.

64. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Döhner H, DiNardo CD, Wei AH, Löwenberg B, Appelbaum F, Craddock C, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D, Ossenkoppele GJ, Röllig C, Sierra J, Stein EM, Tallman MS, Tien HF, Wang J, Wierzbowska A. Blood. 2024 Nov 21;144(21):2169-2173.

63. Genetic Risk Stratification and Outcomes Among Treatment-Naive Patients With AML Treated With Venetoclax and Azacitidine. Döhner H, Pratz KW, DiNardo CD, Wei AH, Jonas BA, Pullarkat V, Thirman MJ, Récher C, Schuh AC, Babu S, Li X, Ku G, Liu Z, Sun Y, Potluri J, Dail M, Chyla B, Pollyea DA. Blood. 2024 Nov 21;144(21):2211-2222.

62. Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the phase 3 CLL14 study. Al-Sawaf O, Robrecht S, Zhang C, Olivieri S, Chang YM, Fink AM, Tausch E, Schneider C, Ritgen M, Kreuzer KA, Sivcheva L, Niemann CU, Schwarer AP, Loscertales J, Weinkove R, Strumberg D, Kilfoyle A, Manzoor BS, Jawaid D, Emechebe N, Devine J, Boyer M, Runkel ED, Eichhorst B, Stilgenbauer S, Jiang Y, Hallek MJ, Fischer K. Blood. 2024 Oct 31;144(18):1924-1935.

61. T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia. Roessner PM, Seufert I, Chapaprieta V, Jayabalan R, Briesch H, Massoni-Badosa R, Boskovic P, Benckendorff J, Roider T, Arseni L, Coelho M, Chakraborty S, Vaca AM, Sivina M, Muckenhuber M, Rodriguez-Rodriguez S, Bonato A, Herbst SA, Zapatka M, Sun C, Kretzmer H, Naake T, Bruch PM, Czernilofsky F, Ten Hacken E, Schneider M, Helm D, Yosifov DY, Kauer J, Danilov AV, Bewarder M, Heyne K, Schneider C, Stilgenbauer S, Wiestner A, Mallm JP, Burger JA, Efremov DG, Lichter P, Dietrich S, Martin-Subero JI, Rippe K, Seiffert M. Blood. 2024 Aug 1;144(5):510-524.

60. Comparison of R-CHOP-14 and R-mini-CHOP in older adults with diffuse large B-cell lymphoma-A retrospective multicenter cohort study. Dilbaz ZG, Denker S, Ankermann C, Bittenbring JT, Kaddu-Mulindwa D, Kunte AS, Hünecke S, Poeschel V, Stilgenbauer S, Thurner L, Na IK, Bewarder M, Christofyllakis K. Eur J Haematol. 2024 Nov;113(5):675-684. Epub 2024 Jul 31.

59. Proposals for Revised International Working Group-European LeukemiaNet Criteria for Anemia Response in Myelofibrosis. Tefferi A, Barosi G, Passamonti F, Hernandez-Boluda JC, Bose P, Döhner K, Ellis M, Gangat N, Garcia JS, Gisslinger H, Gotlib J, Guglielmelli P, Gupta V, Harrison CN, Hexner EO, Hobbs GS, Kiladjian JJ, Koschmieder S, Kröger N, Kuykendall AT, Loscocco GG, Mascarenhas JO, Masarova L, Mesa R, Mora B, Odenike O, Oh ST, Pardanani AD, Patel AA, Pemmaraju N, Rambaldi A, Rampal RK, Sirhan S, Szuber N, Talpaz M, Vachhani P, Vannucchi AM, Barbui T. Blood. 2024 Oct 24;144(17):1813-1820.

58. MoReLife - real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients. Jilg S, Schwaab J, Sockel K, Crodel CC, Brueckl V, Stegelmann F, Jentzsch M, Sasca D, Moyses M, Fuhrmann S, Gundel D, Caduc M, Teichmann LL, Heidel F, Al-Ali HK, Petrides PE. Ann Hematol. 2024 Oct;103(10):4065-4077. Epub 2024 Jul 29.

57. Health-related quality of life in patients with Waldenström macroglobulinemia: results from the ASPEN trial. Tedeschi A, Tam CS, Owen RG, Buske C, Leblond V, Dimopoulos M, Garcia-Sanz R, Castillo JJ, Trotman J, Treon SP, Yang K, Tang B, Allewelt H, Patel S, Chan WY, Cohen A, Chen S, Barnes G. Future Oncol. 2024;20(25):1789-1798. Epub 2024 Jul 29.

56. The role of trephine bone marrow biopsies in the era of measurable residual disease-Results from the CLL10 trial of the German CLL Study Group (GCLLSG). Kutsch N, Robrecht S, Fink A, Lange E, Weide R, Kiehl MG, Sökler M, Schlag R, Vehling-Kaiser U, Köchling G, Plöger C, Gregor M, Plesner T, Clausen MR, Oschlies I, Ritgen M, Herling M, Fischer K, Döhner H, Wendtner CM, Kreuzer KA, Stilgenbauer S, Hallek M, Böttcher S, Klapper W, Eichhorst B. Hemasphere. 2024 Jul 24;8(7):e126. eCollection 2024 Jul.

55. Long-range inhibition from prelimbic to cingulate areas of the medial prefrontal cortex enhances network activity and response execution Utashiro N, MacLaren DAA, Liu YC, Yaqubi K, Wojak B, Monyer H. Nat Commun. 2024 Jul 10;15(1):5772.

54. Impairment of α-tubulin and F-actin interactions of GJB3 induces aneuploidy in urothelial cells and promotes bladder cancer cell invasion. Liu J, Wang X, Jiang W, Azoitei A, Eiseler T, Eckstein M, Hartmann A, Stilgenbauer S, Elati M, Hohwieler M, Kleger A, John A, Wezel F, Zengerling F, Bolenz C, Günes C. Cell Mol Biol Lett. 2024 Jul 2;29(1):94.

53. Venetoclax resistance in acute lymphoblastic leukemia is characterized by increased mitochondrial activity and can be overcome by co-targeting oxidative phosphorylation. Enzenmüller S, Niedermayer A, Seyfried F, Muench V, Tews D, Rupp U, Tausch E, Groß A, Fischer-Posovszky P, Walther P, Stilgenbauer S, Kestler HA, Debatin KM, Meyer LH. Cell Death Dis. 2024 Jul 3;15(7):475.

52. FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN). Isfort S, von Bubnoff N, Al-Ali HK, Becker H, Götze T, le Coutre P, Griesshammer M, Moskwa C, Wohn L, Riedel J, Palandri F, Manz K, Hochhaus A, Döhner K, Heidel FH. Ann Hematol. 2024 Aug;103(8):2775-2785. Epub 2024 Jul 5.

51. Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial. Borchmann P, Ferdinandus J, Schneider G, Moccia A, Greil R, Hertzberg M, Schaub V, Hüttmann A, Keil F, Dierlamm J, Hänel M, Novak U, Meissner J, Zimmermann A, Mathas S, Zijlstra JM, Fosså A, Viardot A, Hertenstein B, Martin S, Giri P, Scholl S, Topp MS, Jung W, Vucinic V, Beck HJ, Kerkhoff A, Unger B, Rank A, Schroers R, Zum Büschenfelde CM, de Wit M, Trautmann-Grill K, Kamper P, Molin D, Kreissl S, Kaul H, von Tresckow B, Borchmann S, Behringer K, Fuchs M, Rosenwald A, Klapper W, Eich HT, Baues C, Zomas A, Hallek M, Dietlein M, Kobe C, Diehl V; German Hodgkin Study Group; Swiss Group for Clinical Cancer Research; Arbeitsgemeinschaft Medikamentöse Tumortherapie; Nordic Lymphoma Group; Australasian Leukaemia and Lymphoma Group. Lancet. 2024 Jul 27;404(10450):341-352. Epub 2024 Jul 3.

50. Author Correction: Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study. Morschhauser F, Dahiya S, Palomba ML, Martin Garcia-Sancho A, Reguera Ortega JL, Kuruvilla J, Jäger U, Cartron G, Izutsu K, Dreyling M, Kahl B, Ghesquieres H, Ardeshna K, Goto H, Barbui AM, Abramson JS, Borchmann P, Fleury I, Mielke S, Skarbnik A, de Vos S, Kamdar M, Karmali R, Viardot A, Farazi T, Fasan O, Lymp J, Vedal M, Nishii R, Avilion A, Papuga J, Kumar J, Nastoupil LJ. Nat Med. 2024 Aug;30(8):2374.

49. ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options. Kiladjian JJ, Marin FF, Al-Ali HK, Alvarez-Larrán A, Beggiato E, Bieniaszewska M, Breccia M, Buxhofer-Ausch V, Cerna O, Crisan AM, Danaila CD, De Stefano V, Döhner K, Empson V, Gora-Tybor J, Griesshammer M, Grosicki S, Guglielmelli P, García-Gutierrez V, Heidel FH, Illés A, Tomuleasa C, James C, Koschmieder S, Krauth MT, Krejcy K, Lazaroiu MC, Mayer J, Nagy ZG, Nicolini FE, Palandri F, Pappa V, Reiter AJ, Sacha T, Schlager S, Schmidt S, Terpos E, Unger M, Wölfler A, Cirici BX, Klade C. Ann Hematol. 2024 Jul;103(7):2299-2310.

48. Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications - a HARMONY study. Hernández-Sánchez A, González T, Sobas M, Sträng E, Castellani G, Abáigar M, Valk PJM, Villaverde Ramiro Á, Benner A, Metzeler KH, Azibeiro R, Tettero JM, Martínez-López J, Pratcorona M, Martínez Elicegui J, Mills KI, Thiede C, Sanz G, Döhner K, Heuser M, Haferlach T, Turki AT, Reinhardt D, Schulze-Rath R, Barbus M, Hernández-Rivas JM, Huntly B, Ossenkoppele G, Döhner H, Bullinger L. Leukemia. 2024 Sep;38(9):1929-1937. Epub 2024 Jul 4.

47. Refinement of the prognostic impact of somatic CEBPA bZIP domain mutations in acute myeloid leukemia: Results of the AML Study Group (AMLSG). Rücker FG, Corbacioglu A, Krzykalla J, Cocciardi S, Lengerke C, Germing U, Wulf G, Samra MA, Teichmann LL, Lübbert M, Kühn MWM, Bentz M, Westermann J, Bullinger L, Gaidzik VI, Meid A, Aicher S, Stegelmann F, Weber D, Schrade A, Thol F, Heuser M, Ganser A, Benner A, Döhner H, Döhner K; German‐Austrian Acute Myeloid Leukemia Study Group (AMLSG). Hemasphere. 2024 Jul 15;8(7):e123. eCollection 2024 Jul.

46. The impact of MICB mismatches in unrelated haematopoietic stem cell transplantation. Amann EM, Gowdavally S, Tsamadou C, Platzbecker U, Sala E, Wagner-Drouet E, Valerius T, Kröger N, Wulf G, Einsele H, Thurner L, Schaefer-Eckart K, Freitag S, Casper J, Dürholt M, Kaufmann M, Hertenstein B, Klein S, Ringhoffer M, Frank S, Saal T, Schmid-Möglich A, Neuchel C, Schrezenmeier H, Mytilineos J, Fürst D. HLA. 2024 Jun;103(6):e15584.

45. The proteogenomic landscape of multiple myeloma reveals insights into disease biology and therapeutic opportunities. Ramberger E, Sapozhnikova V, Ng YLD, Dolnik A, Ziehm M, Popp O, Sträng E, Kull M, Grünschläger F, Krüger J, Benary M, Müller S, Gao X, Murgai A, Haji M, Schmidt A, Lutz R, Nogai A, Braune J, Laue D, Langer C, Khandanpour C, Bassermann F, Döhner H, Engelhardt M, Straka C, Hundemer M, Beule D, Haas S, Keller U, Einsele H, Bullinger L, Knop S, Mertins P, Krönke J. Nat Cancer. 2024 Aug;5(8):1267-1284. Epub 2024 Jun 28.

44. Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ferreri AJM, Illerhaus G, Doorduijn JK, Auer DP, Bromberg JEC, Calimeri T, Cwynarski K, Fox CP, Hoang-Xuan K, Malaise D, Ponzoni M, Schorb E, Soussain C, Specht L, Zucca E, Buske C, Jerkeman M, Dreyling M; EHA and ESMO Guidelines Committees. Hemasphere. 2024 Jun 4;8(6):e89. eCollection 2024 Jun.

43. Genetic alterations in chronic lymphocytic leukemia and plasma cell neoplasms - a practical guide to WHO HAEM5.Tausch E, López C, Stilgenbauer S, Siebert R. Med Genet. 2024 Mar 6;36(1):47-57. eCollection 2024 Apr.

42. T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia. Roessner PM, Seufert I, Chapaprieta V, Jayabalan R, Briesch H, Massoni-Badosa R, Boskovic P, Beckendorff J, Roider T, Arseni L, Coelho M, Chakraborty S, Vaca A, Sivina M, Muckenhuber M, Rodriguez-Rodriguez S, Bonato A, Herbst SA, Zapatka M, Sun C, Kretzmer H, Naake T, Bruch PM, Czernilofsky F, Ten Hacken E, Schneider M, Helm D, Yosifov DY, Kauer J, Danilov AV, Bewarder M, Heyne K, Schneider C, Stilgenbauer S, Wiestner A, Mallm JP, Burger JA, Efremov DG, Lichter P, Dietrich S, Martín-Subero JI, Rippe K, Seiffert M. Blood. 2024 Aug 1;144(5):510-524.

41. Fludarabine, cyclophosphamide, and rituximab as first-line treatment in patients with chronic lymphocytic leukemia: A long-term analysis of the German CLL Study Group (GCLLSG) registry. Kutsch N, Giza A, Robrecht S, Stumpf J, Federhen A, Stoltefuß A, Vehling-Kaiser U, Koenigsmann M, Tausch E, Schneider C, Stilgenbauer S, Illmer T, Schlag R, Dörfel S, Gaska T, Kiehl M, Müller-Hagen S, Moorahrend E, Linde H, Schlenska-Lange A, von Tresckow J, Fischer K, Eichhorst B, Hallek M, Fink AM. Eur J Haematol. 2024 Aug;113(2):235-241. Epub 2024 May 1.

40. Safety and tolerability of AMG 330 in adults with relapsed/refractory AML: a phase 1a dose-escalation study. Ravandi F, Subklewe M, Walter RB, Vachhani P, Ossenkoppele G, Buecklein V, Döhner H, Jongen-Lavrencic M, Baldus CD, Fransecky L, Pardee TS, Kantarjian H, Yen PK, Mukundan L, Panwar B, Yago MR, Agarwal S, Khaldoyanidi SK, Stein A. Leuk Lymphoma. 2024 Sep;65(9):1281-1291. Epub 2024 May 7.

39. Impact of busulfan versus treosulfan dose intensity in myelofibrosis undergoing hematopoietic cell transplantation. Gagelmann N, Schuh C, Flossdorf S, Kunadt D, Stelljes M, Blau IW, Brecht A, Bethge W, Schroeder T, Wulf G, Sala E, Bug G, Fleischhauer K, Kröger N; German Registry for Stem Cell Transplantation, DRST. Am J Hematol. 2024 Aug;99(8):1540-1549. Epub 2024 May 14.

38. ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-2024 update. Malcikova J, Pavlova S, Baliakas P, Chatzikonstantinou T, Tausch E, Catherwood M, Rossi D, Soussi T, Tichy B, Kater AP, Niemann CU, Davi F, Gaidano G, Stilgenbauer S, Rosenquist R, Stamatopoulos K, Ghia P, Pospisilova S. Leukemia. 2024 Jul;38(7):1455-1468. Epub 2024 May 16.

37. The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network. Fischer L, Jiang L, Dürig J, Schmidt C, Stilgenbauer S, Bouabdallah K, Solal-Celigny P, Scholz CW, Feugier P, de Wit M, Trappe RU, Hallek M, Graeven U, Hänel M, Hoffmann M, Delwail V, Macro M, Greiner J, Giagounidis AAN, Dargel B, Durot E, Foussard C, Silkenstedt E, Weigert O, Pott C, Klapper W, Hiddemann W, Unterhalt M, Hoster E, Ribrag V, Dreyling M. Leukemia. 2024 Jun;38(6):1307-1314. Epub 2024 Apr 27.

36. Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study. Morschhauser F, Dahiya S, Palomba ML, Martin Garcia-Sancho A, Reguera Ortega JL, Kuruvilla J, Jäger U, Cartron G, Izutsu K, Dreyling M, Kahl B, Ghesquieres H, Ardeshna K, Goto H, Barbui AM, Abramson JS, Borchmann P, Fleury I, Mielke S, Skarbnik A, de Vos S, Kamdar M, Karmali R, Viardot A, Farazi T, Fasan O, Lymp J, Vedal M, Nishii R, Avilion A, Papuga J, Kumar J, Nastoupil LJ. Nat Med. 2024 Aug;30(8):2199-2207. Epub 2024 Jun 3.

35. Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations. Langerbeins P, Giza A, Robrecht S, Cramer P, von Tresckow J, Al-Sawaf O, Fink AM, Fürstenau M, Kater A, van der Spek E, Niemann CU, da Cunha-Bang C, Tausch E, Schneider C, Stilgenbauer S, Fischer K, Hallek M, Eichhorst B. Am J Hematol. 2024 Aug;99(8):1620-1623. Epub 2024 May 17.

34. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. Dreyling M, Doorduijn J, Giné E, Jerkeman M, Walewski J, Hutchings M, Mey U, Riise J, Trneny M, Vergote V, Shpilberg O, Gomes da Silva M, Leppä S, Jiang L, Stilgenbauer S, Kerkhoff A, Jachimowicz RD, Celli M, Hess G, Arcaini L, Visco C, van Meerten T, Wirths S, Zinzani PL, Novak U, Herhaus P, Benedetti F, Sonnevi K, Hanoun C, Hänel M, Dierlamm J, Pott C, Klapper W, Gözel D, Schmidt C, Unterhalt M, Ladetto M, Hoster E. Lancet. 2024 May 25;403(10441):2293-2306. Epub 2024 May 2.

33. First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial. Fürstenau M, Kater AP, Robrecht S, von Tresckow J, Zhang C, Gregor M, Thornton P, Staber PB, Tadmor T, Lindström V, Juliusson G, Janssens A, Levin MD, da Cunha-Bang C, Schneider C, Goldschmidt N, Vandenberghe E, Rossi D, Benz R, Nösslinger T, Heintel D, Poulsen CB, Christiansen I, Frederiksen H, Enggaard L, Posthuma EFM, Issa DE, Visser HPJ, Bellido M, Kutsch N, Dürig J, Stehle A, Vöhringer M, Böttcher S, Schulte C, Simon F, Fink AM, Fischer K, Holmes EE, Kreuzer KA, Ritgen M, Brüggemann M, Tausch E, Stilgenbauer S, Hallek M, Niemann CU, Eichhorst B. Lancet Oncol. 2024 Jun;25(6):744-759.

32. Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia. Stilgenbauer S, Tausch E, Roberts AW, Davids MS, Eichhorst B, Hallek M, Hillmen P, Schneider C, Schetelig J, Böttcher S, Kater AP, Jiang Y, Boyer M, Popovic R, Ghanim MT, Moran M, Sinai WJ, Wang X, Mukherjee N, Chyla B, Wierda WG, Seymour JF. Blood Adv. 2024 Apr 23;8(8):1992-2004.

31. Reassessing the Chronic Lymphocytic Leukemia International Prognostic Index in the era of targeted therapies. Langerbeins P, Giza A, Robrecht S, Cramer P, von Tresckow J, Al-Sawaf O, Fink AM, Fürstenau M, Kutsch N, Simon F, Goede V, Hoechstetter MA, Niemann CU, da Cunha-Bang C, Kater AP, Dubois J, Gregor M, Staber PB, Tausch E, Schneider C, Stilgenbauer S, Eichhorst B, Fischer K, Hallek MJ. Blood. 2024 Jun 20;143(25):2588-2598.

30. Acalabrutinib, venetoclax and obinutuzumab in relapsed/refractory CLL: Final efficacy and ctDNA analysis of the CLL2-BAAG trial. Fürstenau M, Giza A, Weiss J, Kleinert F, Robrecht S, Franzen F, Stumpf J, Langerbeins P, Al-Sawaf O, Simon F, Fink AM, Schneider C, Tausch E, Schetelig J, Dreger P, Böttcher S, Fischer K, Kreuzer KA, Ritgen M, Schilhabel A, Brüggemann M, Stilgenbauer S, Eichhorst B, Hallek M, Cramer P. Blood. 2024 Jul 18;144(3):272-282.

29. Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial. Cramer P, von Tresckow J, Fink AM, Robrecht S, Giza A, Tausch E, Müller L, Knauf W, Zingerle M, Al-Sawaf O, Langerbeins P, Fischer K, Kreuzer KA, Kneba M, Wendtner CM, Stilgenbauer S, Eichhorst B, Hallek M. Am J Hematol. 2024 Jun;99(6):1192-1195. Epub 2024 Apr 5.

28. Precision hematology: Navigating the evolution of diagnostic classifications in the era of globalized medicine. Macintyre E, Döhner K, Grønbæk K, Dreyling M, Huntly B, Almeida A, Gribben J; EHA Board. Hemasphere. 2024 Apr 4;8(4):e65. eCollection 2024 Apr.

27. Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries. Lübke J, Christen D, Schwaab J, Kaiser A, Naumann N, Shoumariyeh K, Jentzsch M, Sockel K, Schaffrath J, Ayuk FA, Stelljes M, Hilgendorf I, Sala E, Kaivers J, Schönland S, Wittke C, Hertenstein B, Radsak M, Kaiser U, Brückl V, Kröger N, Brümmendorf TH, Hofmann WK, Klein S, Jost E, Reiter A, Panse J. Leukemia. 2024 Apr;38(4):810-821. Epub 2024 Mar 6.

26. ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options. Kiladjian JJ, Marin FF, Al-Ali HK, Alvarez-Larrán A, Beggiato E, Bieniaszewska M, Breccia M, Buxhofer-Ausch V, Cerna O, Crisan AM, Danaila CD, De Stefano V, Döhner K, Empson V, Gora-Tybor J, Griesshammer M, Grosicki S, Guglielmelli P, García-Gutierrez V, Heidel FH, Illés A, Tomuleasa C, James C, Koschmieder S, Krauth MT, Krejcy K, Lazaroiu MC, Mayer J, Nagy ZG, Nicolini FE, Palandri F, Pappa V, Reiter AJ, Sacha T, Schlager S, Schmidt S, Terpos E, Unger M, Wölfler A, Cirici BX, Klade C. Ann Hematol. 2024 Jul;103(7):2299-2310. Epub 2024 Mar 4.

25. CDK6 protein expression is associated with disease progression and treatment resistance in multiple myeloma. Steinhart J, Möller P, Kull M, Krönke J, Barth TFE. Hemasphere. 2024 Jan 27;8(1):e32. eCollection 2024 Jan.

24. There's life in the old dog yet: immunochemotherapy in Waldenström's macroglobulinemia. Kastritis E, Buske C. Leukemia. 2024 Jun;38(6):1435-1436. Epub 2024 Mar 7.

23. How to manage waldenström's macroglobulinemia in 2024. Grunenberg A, Buske C. Cancer Treat Rev. 2024 Mar 5;125:102715. Epub 2024 Mar 5.

22. Venetoclax Initiation in Chronic Lymphocytic Leukemia: International Insights and Innovative Approaches for Optimal Patient Care. Anderson MA, Walewska R, Hackett F, Kater AP, Montegaard J, O'Brien S, Seymour JF, Smith M, Stilgenbauer S, Whitechurch A, Brown JR. Cancers (Basel). 2024 Feb 28;16(5):980.

21. Neurologic Complications of the Central Nervous System after Allogeneic Stem Cell Transplantation: The Role of Transplantation-Associated Thrombotic Microangiopathy as a Potential Underreported Cause. Sala E, Neagoie AM, Lewerenz J, Saadati M, Benner A, Gantner A, Wais V, Döhner H, Bunjes D. Transplant Cell Ther. 2024 Jun;30(6):586.e1-586.e11. Epub 2024 Mar 19. PMID: 38508452

20. Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia. Burmeister T, Ströh AS, Kehden B, Trautmann H, Meyer C, Marschalek R, Larghero P, Schwartz S, Steffen B, Spriewald B, Heinicke T, Jäkel N, Westermann J, Nachtkamp K, Viardot A, Topp MS, Neumann M, Baldus CD, Gökbuget N, Brüggemann M. Leukemia. 2024 Jul;38(7):1455-1468. Epub 2024 May 16.

19. Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia. Stilgenbauer S,Tausch E, Roberts AW, Davids MS, Eichhorst B, Hallek MJ, Hilmen P, Schneider C, Schetelig J, Böttcher S, Kater AP, Jiang Y, Boyer M, Popovic R, Ghanim MT, Moran M, Sinai WJ, Wang X, Mukherjee N, Chyla B, Wierda WG, Seymour JF. Blood Adv. 2024 Apr 23;8(8):1992-2004.

18. Biomarker analysis of the ASPEN study comparing zanubrutinib to ibrutinib in patients with Waldenström Macroglobulinemia. Tam CS, Opat S, D'Sa SP, Jurczak W, Lee HP, Cull G, Owen RG, Marlton P, Wahlin BE, Garcia-Sanz R, McCarthy H, Mulligan SP, Tedeschi A, Castillo JJ, Czyz J, Fernández de Larrea C, Belada D, Libby EN, Matous JV, Motta M MD, Siddiqi T, Tani M, Trněný M, Minnema MC, Buske C, Leblond V, Treon SP, Trotman J, Wu B, Yu Y, Shen Z Dr, Chan WY, Schneider J, Allewelt H, Cohen A, Dimopoulos MA. Blood Adv. 2024 Apr 9;8(7):1639-1650.

17. Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts. Appelbaum JS, Wei AH, Mandrekar SJ, Tiong IS, Chua CC, Teh TC, Fong CY, Ting SB, Weber D, Benner A, Hill H, Saadati M, Yin J, Stone RM, Garcia-Manero G, Erba HP, Uy GL, Marcucci G, Larson RA, Thomas A, Freeman SD, Almuina NM, Döhner K, Thomas I, Russel NH, Döhner H, Othus M, Estey EH, Walter RB. Leukemia. 2024 Feb;38(2):389-392. Epub 2024 Jan 23.

16. Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results From the European Mantle Cell Lymphoma Elderly Trial. Hoster E, Delfau-Larue MH, Macintyre E, Jiang L, Stilgenbauer S, Vehling-Kaiser U, Salles G, Thieblemont C, Tilly H, Wirths S, Feugier P, Hübel K, Schmidt C, Ribrag V, Kluin-Nelemans JC, Dreyling M, Pott C; European MCL MRD Working Group and the European MCL Network. J Clin Oncol. 2024 Feb 10;42(5):538-549. Epub 2023 Nov 22.

15. Geriatric Assessment of Older Patients Receiving Trabectedin in First-Line Treatment for Advanced Soft Tissue Sarcomas: The E-TRAB Study from The German Interdisciplinary Sarcoma Group (GISG-13). Kasper B, Pink D, Rothermundt C, Richter S, Augustin M, Kollar A, Kunitz A, Eisterer W, Gaidzik V, Brodowicz T, Egerer G, Reichardt P, Hohenberger P, Schuler MK. Cancers (Basel). 2024 Jan 28;16(3):558.

14. Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Pratz KW, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Döhner H, Récher C, Fiedler W, Yamamoto K, Wang J, Yoon SS, Wolach O, Yeh SP, Leber B, Esteve J, Mayer J, Porkka K, Illés Á, Lemoli RM, Turgut M, Ku G, Miller C, Zhou Y, Zhang M, Chyla B, Potluri J, DiNardo CD. Am J Hematol. 2024 Apr;99(4):615-624. Epub 2024 Feb 11.

13. Impact of individualized treatment on recovery from fatigue and return to work in survivors of advanced-stage Hodgkin's lymphoma: results from the randomized international GHSG HD18 trial. Ferdinandus J, Müller H, Damaschin C, Jacob AS, Meissner J, Krasniqi F, Mey U, Schöndube D, Thiemer J, Mathas S, Zijlstra J, Greil R, Feuring-Buske M, Markova J, Rüffer JU, Kobe C, Eich HT, Baues C, Fuchs M, Borchmann P, Behringer K. Ann Oncol. 2024 Mar;35(3):276-284. Epub 2023 Dec 5.

12. Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as a therapeutic strategy for acute myeloid leukemia. Bruedigam C, Porter AH, Song A, Vroeg In de Wei G, Stoll T, Straube J, Cooper L, Cheng G, Kahl VFS, Sobinoff AP, Ling VY, Jebaraj BMC, Janardhanan Y, Haldar R, Bray LJ, Bullinger L, Heidel FH, Kennedy GA, Hill MM, Pickett HA, Abdel-Wahab O, Hartel G, Lane SW. Nat Cancer. 2024 Jan;5(1):47-65.

11. Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: randomized phase 3 ASTRAL-2 trial. Roboz GJ, Sanz GF, Griffiths EA, Yee KWL, Kantarjian HM, Récher C, Byrne MT, Patkowska E, Kim HJ, Thomas X, Moors I, Stock W, Illes A, Fenaux P, Miyazaki Y, Yamauchi T, O'Connell C, Hao Y, Keer HN, Azab M, Döhner H. Blood Adv. 2024 Apr 23;8(8):2020-2029.

10. CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges. Werner R, Haug A, Buske C, Heidegger S, Illert AL, Bassermann F, Herhaus P, Buck A, Duell J, Topp MS, Kraus S, Einsele H, Lapa C, Raderer M, Lenz G, Habringer S, von Tresckow B, Keller U. Nuklearmedizin. 2024 Apr;63(2):57-61. Epub 2024 Jan 8. PMID: 38190998

9. Durable Response After Tisagenlecleucel in Adults With Relapsed/Refractory Follicular Lymphoma: ELARA Trial Update. Dreyling M, Fowler NH, Dickinson M, Martínez-López J, Kolstad A, Butler J, Ghosh M, Popplewell L, Chavez JC, Bachy E, Kato K, Harigae H, Kersten MJ, Andreadis CB, Riedell PA, Ho PJ, Perez-Simon JA, Chen AI, Nastoupil LJ, von Tresckow B, Ferreri AJ, Teshima T, Patten PE, McGuirk JP, Petzer AL, Offner F, Viardot A, Zinzani PL, Malladi R, Paule I, Zia A, Awasthi R, Han X, Germano D, O'Donovan DS, Ramos RJ, Maier HJ, Masood A, Thieblemont C, Schuster SJ. Blood. 2024 Apr 25;143(17):1713-1725.

8. Upper and/or Lower Respiratory Tract Infection Caused by Human Metapneumovirus After Allogeneic Hematopoietic Stem Cell Transplantation. Piñana JL, Tridello G, Xhaard A, Wendel L, Montoro J, Vazquez L, Heras I, Ljungman P, Mikulska M, Salmenniemi U, Perez A, Kröger N, Cornelissen J, Sala E, Martino R, Geurten C, Byrne J, Maertens J, Kerre T, Martin M, Pascual MJ, Yeshurun M, Finke J, Groll AH, Shaw PJ, Blijlevens N, Arcese W, Ganser A, Suarez-Lledo M, Alzahrani M, Choi G, Forcade E, Paviglianiti A, Solano C, Wachowiak J, Zuckerman T, Bader P, Clausen J, Mayer J, Schroyens W, Metafuni E, Knelange N, Averbuch D, de la Camara R. J Infect Dis. 2024 Jan 12;229(1):83-94.

7. Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial. Al-Sawaf O, Ligtvoet R, Robrecht S, Stumpf J, Fink AM, Tausch E, Schneider C, Boettcher S, Mikusko M, Ritgen M, Schetelig J, von Tresckow J, Vehling-Kaiser U, Gaska T, Wendtner CM, Chapuy B, Fischer K, Kreuzer KA, Stilgenbauer S, Staber P, Niemann C, Hallek M, Eichhorst B. Nat Med. 2024 Jan;30(1):240-248. Epub 2023 Dec 9.

6. How I treat refractory and relapsed acute myeloid leukemia. Thol FR, Döhner H, Ganser A. Blood. 2024 Jan 4;143(1):11-20.

5. Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML-001. Ravandi F, Döhner H, Wei AH, Montesinos P, Pfeilstöcker M, Papayannidis C, Lai Y, Wang K, See WL, de Menezes DL, Petrlik E, Prebet T, Roboz GJ. Br J Haematol. 2024 Mar;204(3):877-886. Epub 2023 Nov 12. PMID: 37952982

4. Low-dose azacitidine, pioglitazone and all-trans retinoic acid is safe in patients aged ≥ 60 years with acute myeloid leukemia refractory to standard induction chemotherapy (AMLSG 26-16/AML-ViVA): results of the safety run-in phase. Heudobler D, Luke F, Hahn J, Grube M, Schlosser P, Kremers S, Sudhoff T, Westermann J, Hutter-Kronke ML, Schlenk RF, Weber D, Paschka P, Zeman F, Dohner H, Herr W, Reichle A, Thomas S. Haematologica. 2024 Apr 1;109(4):1274-1278.

3. Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma. Hess G, Dreyling M, Oberic L, Gine E, Zinzani PL, Linton K, Vilmar A, Jerkeman M, Chen JMH, Ohler A, Stilgenbauer S, Thieblemont C, Lambert J, Zilioli VR, Sancho JM, Jimenez-Ubieto A, Fischer L, Eyre TA, Keeping S, Park JE, Wu JJ, Nunes A, Reitan J, Wade SW, Salles G. Leuk Lymphoma. 2024 Jan;65(1):14-25. Epub 2024 Jan 10.

2. Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma. Fuchs M, Jacob AS, Kaul H, Kobe C, Kuhnert G, Pabst T, Greil R, Bröckelmann PJ, Topp MS, Just M, Hertenstein B, Soekler M, Vogelhuber M, Zijlstra JM, Keller UB, Krause SW, Dührsen U, Meissner J, Viardot A, Eich HT, Baues C, Diehl V, Rosenwald A, Buehnen I, von Tresckow B, Dietlein M, Borchmann P, Engert A, Eichenauer DA. Leukemia. 2024 Jan;38(1):160-167. Epub 2023 Oct 16.

1. Addendum to the German Consensus Recommendations on Ponatinib in the Treatment of Chronic Myeloid Leukemia. Saussele S, La Rosée P, Kiani A, Haverkamp W, Jentsch-Ullrich K, Stegelmann F, Rieger C, Waller CF, Franke GN, Junghanss C, Kirchmair R, Theurl M, le Coutre P. Acta Haematol. 2024;147(3):344-351. Epub 2023 Oct 17. PMID: 37848002 Review.